Cancer chemotherapy and somatic cell mutation
| Autor: | Yoshihiro Wakazono, Keigo Hamahata, Masaru Kubota, Ying-Wei Lin, Seiji Koishi, Haruyo Hirota, Machiko Sawada |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Mutation
Chemotherapy Somatic cell Health Toxicology and Mutagenesis medicine.medical_treatment T-cell receptor Mutant Cancer Antineoplastic Agents Neoplasms Second Primary Biology medicine.disease medicine.disease_cause Genetic determinism Neoplasms Immunology Genetics Cancer research medicine Humans Neoplasm |
| Zdroj: | Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 470:93-102 |
| ISSN: | 1383-5718 |
| DOI: | 10.1016/s1383-5742(00)00043-0 |
| Popis: | The occurrence of a second neoplasm is one of the major obstacles in cancer chemotherapy. The elucidation of the genotoxic effects induced by anti-cancer drugs is considered to be helpful in identifying the degree of cancer risk. Numerous investigations on cancer patients after chemotherapy have demonstrated: (i) an increase in the in vivo somatic cell mutant frequency (Mf) at three genetic loci, including hypoxanthine-guanine phosphoribosyl-transferase (hprt), glycophorin A (GPA), and the T-cell receptor (TCR), and (ii) alterations in the mutational spectra of hprt mutants. However, the time required for and the degree of such changes are quite variable among patients even if they have received the same chemotherapy, suggesting the existence of underlying genetic factor(s). Accordingly, some cancer patients prior to chemotherapy as well as patients with cancer-prone syndrome have been found to show an elevated Mf. Based on the information obtained from somatic cell mutation assays, an individualized chemotherapy should be considered in order to minimize the risk of a second neoplasm. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect